Last reviewed · How we verify

NCT04499898

Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding

Recruiting now Phase 2, PHASE3 Last updated 5 August 2020
What this trial tests

Phase 2, PHASE3 trial testing Carvedilol in Esophageal Varices in 306 participants. Currently enrolling.

Timeline
1 October 2018
Primary endpoint
1 December 2030
10 December 2030

Quick facts

Lead sponsorSherief Abd-Elsalam
PhasePhase 2, PHASE3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment306
Start date1 October 2018
Primary completion1 December 2030
Estimated completion10 December 2030
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sherief Abd-Elsalam — full company profile →

Who can join

18 and older, any sex, with Esophageal Varices. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Carvedilol

Trials testing the same drug.

Other recruiting trials for Esophageal Varices

Currently open trials in the same condition.

Other Sherief Abd-Elsalam trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04499898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing